Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma

NCT00057902 is an interventional clinical trial that is for Lymphoma conditions and was started in February of 2003. This trial has 50 people enrolled who are within the adult and senior age range. This trial is funded by NIH. The specific sponsors / contributors of this trial are as follows: National Cancer Institute (NCI). The following interventions were used in this trial: (drug) bortezomib, (drug) cyclophosphamide, (drug) doxorubicin hydrochloride, (drug) etoposide, (drug) prednisone, and (drug) vincristine sulfate.